Advances in the development of thrombin inhibitors (Q28182480)

Expert Opinion on Investigational Drugs

Europe PubMed Central

title

Advances in the development of thrombin inhibitors (English)

0 references

3

J Sturzebecher

0 references

author name string

T Steinmetzer

series ordinal

1

0 references

J Hauptmann

series ordinal

2

0 references

language of work or name

English

0 references

publication date

May 2001

0 references

published in

0 references

volume

10

0 references

issue

5

0 references

page(s)

845-64

0 references

cites work

The structure of a complex of recombinant hirudin and human alpha-thrombin

1 reference

https://api.crossref.org/works/10.1517/13543784.10.5.845

New inhibitors of thrombin and other trypsin-like proteases: hydrogen bonding of an aromatic cyano group with a backbone amide of the P1 binding site replaces binding of a basic side chain

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.10.5.845

Novel natural product 5,5-trans-lactone inhibitors of human alpha-thrombin: mechanism of action and structural studies

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.10.5.845

Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.10.5.845

Enzyme flexibility, solvent and 'weak' interactions characterize thrombin-ligand interactions: implications for drug design

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.10.5.845

Design of P1' and P3' residues of trivalent thrombin inhibitors and their crystal structures

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.10.5.845

Design and evaluation of novel bivalent thrombin inhibitors based on amidinophenylalanines

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.10.5.845

Bifunctional peptide boronate inhibitors of thrombin: crystallographic analysis of inhibition enhanced by linkage to an exosite 1 binding peptide

20 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543784.10.5.845

Direct thrombin inhibitors: current status and future prospects

20 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.845

Synthetic inhibitors of thrombin and factor Xa: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.845

Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.845

How the protease thrombin talks to cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.845

Argatroban During Percutaneous Transluminal Coronary Angioplasty: Results of a Dose-Verification Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.845

A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.845

Bivalirudin: a new generation antithrombotic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.845

Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.845

The mechanism of binding of low-molecular-weight active site inhibitors to human alpha-thrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.845

Effects of melagatran, a novel direct thrombin inhibitor, during experimental septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.845

Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.845

Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.845

The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.845

Structural modification of an orally active thrombin inhibitor, LB30057: replacement of the D-pocket-binding naphthyl moiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.845

Studies towards the identification of potent, selective and bioavailable thrombin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.845

In vitro and in vivo studies of AT-1362, a newly synthesized and orally active inhibitor of thrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.845

Design of potent bivalent thrombin inhibitors based on hirudin sequence: incorporation of nonsubstrate-type active site inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.845

Low molecular weight heparin in unstable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.845

Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.845